SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-23-014168
Filing Date
2023-11-13
Accepted
2023-11-13 16:31:05
Documents
49
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tenx_10q.htm   iXBRL 10-Q 688582
2 CERTIFICATION tenx_ex311.htm EX-31.1 15271
3 CERTIFICATION tenx_ex312.htm EX-31.2 14910
4 CERTIFICATION tenx_ex321.htm EX-32.1 5927
5 CERTIFICATION tenx_ex322.htm EX-32.2 6026
  Complete submission text file 0001654954-23-014168.txt   3151486

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tenx-20230930.xsd EX-101.SCH 37953
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20230930_lab.xml EX-101.LAB 202887
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20230930_cal.xml EX-101.CAL 30797
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20230930_pre.xml EX-101.PRE 170115
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20230930_def.xml EX-101.DEF 106925
43 EXTRACTED XBRL INSTANCE DOCUMENT tenx_10q_htm.xml XML 351684
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 231399350
SIC: 2834 Pharmaceutical Preparations